The Final Hurdle in the Covid-19 Vaccine Race Is Bureaucracy (2)

Nov. 18, 2020, 1:14 PM

Making vaccines that are safe and effective is certainly the hard part of the race to pull humanity from the pandemic brink. Promising results are pouring in. On Nov. 9, Pfizer Inc. and its German partner BioNTech SE said early findings showed their vaccine prevented more than 90% of symptomatic infections in a trial of tens of thousands of volunteers. On Nov. 16, Moderna Inc. reported a 94.5% prevention rate for its vaccine, with a 30,000-plus test group. Today, Pfizer-BioNTech announced that a final analysis of its trials showed that its vaccine was 95% effective. AstraZeneca Plc is expected to report on ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.